33631-09-3

Basic information

• Product Name: 3-AMINO-4-METHOXYPYRIDINE
• Synonyms: 3-AMINO-4-METHOXYPYRIDINE;4-METHOXY-PYRIDIN-3-YLAMINE;CBI-BB ZERO/004846;3-Amino-4-methoxypyridine ,98%;4-Methoxy-3-PyridinaMine
• CAS NO: 33631-09-3
• Molecular Formula: C₆H₈N₂O
• Molecular Weight: 124.14
• Product Categories: Heterocycle-Pyridine series
• Mol File: 33631-09-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 83 °C
• Boiling Point: 270.4oC at 760 mmHg
• Flash Point: 117.4oC
• Appearance: /
• Density: 1.139g/cm3
• Vapor Pressure: 0.00684mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.48±0.18(Predicted)
• CAS DataBase Reference: 3-AMINO-4-METHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-4-METHOXYPYRIDINE(33631-09-3)
• EPA Substance Registry System: 3-AMINO-4-METHOXYPYRIDINE(33631-09-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-20/21/22
• Safety Statements: 36/37
• Hazardous Substances Data: 33631-09-3(Hazardous Substances Data)

Usage

Chemical Properties

Off-white solid

InChI:InChI=1/C6H8N2O/c1-9-6-2-3-8-4-5(6)7/h2-4H,7H2,1H3

Upstream product

• 31872-62-5 4-methoxy-3-nitro-pyridine 
• 5435-54-1 4-hydroxy-3-nitropyridine 

Downstream Products

• 109613-97-0 2-bromo-4-methoxy-pyridin-3-amine 
• 74133-20-3 4-methoxypyridine-3-carbonitrile 
• 109613-98-1 2-bromo-3-fluoro-4-methoxypyridine 
• 72016-31-0 orelline 
• 37338-80-0 3,3',4,4'-tetrahydroxy-2,2'-bipyridine-1,1'-dioxide 
• 173435-34-2 3-Amino-2-chloro-4-methoxypyridine 
• 425380-39-8 7-methoxy-1H-pyrrolo[3,2-b]pyridine 
• 1313267-55-8 ethyl (2-bromo-4-methoxypyridin-3-yl)carbamate 
• 1313267-57-0 ethyl (4-methoxy-2-((trimethylsilyl)ethynyl)pyridin-3-yl)carbamate 
• 1374233-61-0 C₈H₁₄N₃O₅S₂⁽¹⁺⁾*C₉H₁₁O₃S^(1-) 
• 1374233-62-1 C₁₈H₁₈FN₃O₅S 
• 1374233-63-2 C₂₃H₂₆FN₃O₅S 
• 1374233-64-3 C₂₂H₂₄FN₃O₅S 
• 1374233-65-4 C₂₃H₂₃F₄N₃O₇S₂ 

Relevant articles and documents

Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action

Ebola virus (EBOV) causes a deadly hemorrhagic fever in humans and non-human primates. There is currently no FDA-approved vaccine or medication to counter this disease. Here, we report on the design, synthesis and anti-viral activities of two classes of compounds which show high potency against EBOV in both in vitro cell culture assays and in vivo mouse models Ebola viral disease. These compounds incorporate the structural features of cationic amphiphilic drugs (CAD), i.e they possess both a hydrophobic domain and a hydrophilic domain consisting of an ionizable amine functional group. These structural features enable easily diffusion into cells but once inside an acidic compartment their amine groups became protonated, ionized and remain trapped inside the acidic compartments such as late endosomes and lysosomes. These compounds, by virtue of their lysomotrophic functions, blocked EBOV entry. However, unlike other drugs containing a CAD moiety including chloroquine and amodiaquine, compounds reported in this study display faster kinetics of accumulation in the lysosomes, robust expansion of late endosome/lysosomes, relatively more potent suppression of lysosome fusion with other vesicular compartments and inhibition of cathepsins activities, all of which play a vital role in anti-EBOV activity. Furthermore, the diazachrysene 2 (ZSML08) that showed most potent activity against EBOV in in vitro cell culture assays also showed significant survival benefit with 100% protection in mouse models of Ebola virus disease, at a low dose of 10 mg/kg/day. Lastly, toxicity studies in vivo using zebrafish models suggest no developmental defects or toxicity associated with these compounds. Overall, these studies describe two new pharmacophores that by virtue of being potent lysosomotrophs, display potent anti-EBOV activities both in vitro and in vivo animal models of EBOV disease.

Manganese salen complexes with acid-base catalytic auxiliary: Functional mimetics of catalase

Antioxidant therapies have been considered for a wide variety of disorders associated with oxidative stress, and synthetic catalytic scavengers of reactive oxygen species would be clinically superior to stoichiometric ones. Among them, salen-manganese complexes (Mn(Salen)) seem promising, because they exhibit dual functions, i.e. superoxide dismutase- and catalase-mimetic activities. We have been developing enzyme-mimetic Mn(Salen) complexes bearing a functional group that enhances their catalytic activity. Here, we describe the design and synthesis of novel Mn(Salen) complexes with general acid-base catalytic functionality, inspired by the reaction mechanism of catalase. As expected, these Mn(Salen) complexes showed superior catalase-like activity and selectivity, while retaining moderate SOD-like activity. An unsubstituted pyridyl group worked well as a functionality to promote catalase-like activity. The introduced functionality did not alter the redox potential suggesting that the auxiliary-modified complex acted as an acid-base catalyst analogous to catalase. We believe that our approach provides a new design principle for sophisticated catalyst design. Further, the compounds described here appear to be good candidates for use in antioxidant therapy.

COMPOUNDS

The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.